Recurrent Non-small Cell Lung Cancer Completed Phase 2 Trials for Bevacizumab (DB00112)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01649947Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase IITreatment
NCT00368992S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung CancerTreatment